# Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma

> **NCT01943422** · PHASE1 · COMPLETED · sponsor: **John Kirkwood** · enrollment: 7 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** High-dose Interferon alfa-2b
- **DRUG:** Vemurafenib

## Key facts

- **NCT ID:** NCT01943422
- **Lead sponsor:** John Kirkwood
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2016-11
- **Final completion:** 2016-12
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2018-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01943422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01943422, "Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01943422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*